Image

Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial

Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial

Recruiting
6-4 years
All
Phase N/A

Powered by AI

Overview

The goal of this multi-center randomized, parallel group trial is to determine the effect of human milk diets ranging between 180 and 200 mL/kg/day on the body composition outcomes of moderately preterm infants born between 27 and 31 weeks of gestation.

Description

Participants will be randomized once they reach 120 mL/kg/day. Clinicians will be able to increase feeds each day as they see fit, until the patient reaches the target goal of 140-160 mL/kg/day or 180-200 mL/kg/day. They will then maintain this volume until 34 weeks postmenstrual age. Researchers will compare these two targets to see if higher feeding volumes prevent faltering growth without causing adverse metabolic outcomes.

Participants will:

  • Have a feeding volume of 180-200 mL/kg/day or a volume of 140-160 mL/kg/day until 34 weeks corrected age
  • Have four body composition assessments with a bioelectrical impedance analyzer throughout study period
  • Have four stool samples collected throughout study period
  • Have four maternal breastmilk samples collected and analyzed throughout the study period
  • Have one blood sample collected at 36 weeks corrected age
  • Have the option to participate in a follow-up survey completed by parents at 2-3 years of age

Eligibility

Inclusion Criteria:

  • Gestational age between 27 0/7 and 31 6/7 weeks
  • Birthweight of 1500 grams or less
  • Human milk feeding during the first 14 days after birth
  • Full enteral feeding (120mL/kg/day or more) within the first 14 days after birth

Exclusion Criteria:

  • Necrotizing enterocolitis stage 2 or greater
  • Spontaneous intestinal perforation
  • Major congenital/chromosomal anomalies
  • Terminal illness requiring limited or withheld support
  • Intention to restrict fluid intake after the first 14 postnatal days due to the presence of a symptomatic patent ductus arteriosus (PDA)
  • Any formula feeding within the first 14 days after birth

Study details
    Prematurity

NCT06420531

University of Alabama at Birmingham

16 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.